Krystal Biotech (KRYS) EBT Margin (2021 - 2025)
Historic EBT Margin for Krystal Biotech (KRYS) over the last 4 years, with Q3 2025 value amounting to 49.05%.
- Krystal Biotech's EBT Margin rose 135400.0% to 49.05% in Q3 2025 from the same period last year, while for Sep 2025 it was 50.1%, marking a year-over-year increase of 263400.0%. This contributed to the annual value of 32.82% for FY2024, which is 73900.0% up from last year.
- Latest data reveals that Krystal Biotech reported EBT Margin of 49.05% as of Q3 2025, which was up 135400.0% from 48.7% recorded in Q2 2025.
- Over the past 5 years, Krystal Biotech's EBT Margin peaked at 1059.79% during Q1 2021, and registered a low of 2.06% during Q1 2024.
- Its 4-year average for EBT Margin is 228.97%, with a median of 48.87% in 2025.
- As far as peak fluctuations go, Krystal Biotech's EBT Margin plummeted by -9082400bps in 2024, and later skyrocketed by 473700bps in 2025.
- Quarter analysis of 4 years shows Krystal Biotech's EBT Margin stood at 1059.79% in 2021, then plummeted by -98bps to 25.29% in 2023, then surged by 111bps to 53.35% in 2024, then decreased by -8bps to 49.05% in 2025.
- Its EBT Margin was 49.05% in Q3 2025, compared to 48.7% in Q2 2025 and 49.43% in Q1 2025.